PT  - JOURNAL ARTICLE
AU  - MANUEL M. GARRIDO
AU  - JOSÉ C. MARTA
AU  - RUY M. RIBEIRO
AU  - LUÍS C. PINHEIRO
AU  - STEFAN HOLDENRIEDER
AU  - JOÃO T. GUIMARÃES
TI  - Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations
AID  - 10.21873/invivo.12643
DP  - 2021 Nov 01
TA  - In Vivo
PG  - 3431--3439
VI  - 35
IP  - 6
4099  - http://iv.iiarjournals.org/content/35/6/3431.short
4100  - http://iv.iiarjournals.org/content/35/6/3431.full
SO  - In Vivo2021 Nov 01; 35
AB  - Background/Aim: Lack of interchangeability between prostate-specific antigen (PSA) assays could have a clinical impact. We compared PSA assays from different manufacturers and calibrations. Patients and Methods: A total of 233 men who underwent prostate biopsy (PSA: 2-10 ng/ml; Beckman Coulter Access® Hybritech® as reference) were enrolled. Total (tPSA) and free PSA (fPSA) were also measured using the Roche cobas® and the Abbott Architect® methods. Results: Roche tPSA values were ≈1% higher than Beckman, while Abbott values were ≈5% lower. Roche had the highest diagnostic sensitivity (92%) compared to Beckman Coulter (87%) and Abbott (85%). Roche fPSA was ≈3% lower and Abbott ≈17% higher than that of Beckman. For the percentage of fPSA, Roche had the highest sensitivity (98%). Conclusion: Roche cobas® and Beckman Coulter Access® Hybritech® tPSA were almost interchangeable. While the agreement was acceptable for tPSA, this did not happen with fPSA and greater efforts for harmonization are required.